Galzahr Karim 4

What Happened

• Galzahr Karim, a director of OS Therapies Inc. (OSTX), was granted options to acquire 50,000 shares on January 22, 2026. The Form 4 lists the acquisition price as $0.00 and records the transaction as an award/derivative (code A). This was a grant of options — not a purchase, sale, or exercise — so it does not represent an immediate cash transaction or a change in outstanding common shares.

Key Details

• Transaction date: January 22, 2026 (grant).
• Filing date: February 13, 2026 — 22 days after the grant (appears later than the typical 2-business-day Form 4 deadline).
• Quantity: options to purchase 50,000 shares; acquisition price listed as $0.00.
• Vesting: options vest in full on the one-year anniversary of the grant (Jan 22, 2027) provided Karim remains a director (per footnote).
• Shares owned after transaction: not specified in the filing.
• Transaction type: Award/derivative (A). This is a grant of rights to buy shares in the future, not an exercise or sale.

Context

• These are stock option awards that will convert into the right to purchase common shares only if/when exercised after vesting; no shares were exercised or sold in this filing. Director awards like this are common compensation; watch future filings for vesting, exercises, or any subsequent sales that would indicate different insider activity.